Restricted accessResearch articleFirst published online 2024-12
Distinct tau pathologies in the nucleus basalis of Meynert between early-onset and late-onset Alzheimer's disease patients revealed by positron emission tomography
Tau accumulation in the nucleus basalis of Meynert (nbM) has been documented in Alzheimer's disease (AD), but its relationship to neuropathological changes in other brain regions and cognitive deficits remains unclear, particularly between early-onset AD (EOAD) and late-onset AD (LOAD).
Objective
To evaluate tau accumulation patterns in the nbM and other brain regions in EOAD and LOAD using 18F-florzolotau PET and examine correlations with cognitive function.
Methods
Thirty-eight amyloid-positive AD patients (15 EOAD, 23 LOAD) and 46 healthy controls underwent 18F-florzolotau PET. Tau levels were quantified in the nbM and Braak-staging regions. Postmortem brain samples were examined to assess 18F-florzolotau binding to tau deposits.
Results
EOAD showed a higher overall tau burden, including in the nbM, compared with LOAD. However, nbM tau levels correlated more strongly with cognitive decline in LOAD than EOAD. The relationship between nbM tau and neocortical tau differed between EOAD and LOAD. Histopathology revealed abundant 18F-florzolotau labeling of neurofibrillary tangles (NFTs) and ghost tangles in AD nbM samples.
Conclusions
This study provides the first in vivo PET evidence of differential nbM tau pathology between EOAD and LOAD, with higher accumulation but weaker correlation to cognition in EOAD. The distinct relationships between nbM and cortical tau in EOAD and LOAD suggest divergent pathological trajectories. 18F-florzolotau PET successfully visualized NFTs and extracellular ghost tangles in the nbM across AD stages. These findings highlight the importance of considering age of onset when evaluating tau pathology and its clinical correlates in AD.
GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health2022; 7: e105–e125.
2.
2020 Alzheimer’s disease facts and figures. Alzheimers Dement2020; 16: 391–460.
3.
ZhuX-CTanLWangH-F, et al.Rate of early onset Alzheimer’s disease: a systematic review and meta-analysis. Ann Transl Med2015; 3: 38.
4.
ReitzCRogaevaEBeechamGW. Late-onset vs nonmendelian early-onset Alzheimer disease: a distinction without a difference?Neurol Genet2020; 6: e512.
5.
Ruiz-AdameM. A systematic review of the indirect and social costs in early and young onset dementias. J Alzheimers Dis2022; 85: 21–29.
6.
WernerPStein-ShvachmanIKorczynAD. Early onset dementia: clinical and social aspects. Int Psychogeriatr2009; 21: 631–636.
7.
KoedamELGELaufferVvan der VliesAE, et al.Early-versus late-onset Alzheimer’s disease: more than age alone. J Alzheimers Dis2010; 19: 1401–1408.
8.
Trejo-LopezJAYachnisATProkopS. Neuropathology of Alzheimer’s disease. Neurotherapeutics2022; 19: 173–185.
9.
Hanna Al-ShaikhFSDuaraRCrookJE, et al.Selective vulnerability of the nucleus basalis of Meynert among neuropathologic subtypes of Alzheimer disease. JAMA Neurol2020; 77: 225–233.
10.
LinCPFrigerioIBoonBDC, et al.Structural (dys)connectivity associates with cholinergic cell density in Alzheimer’s disease. Brain2022; 145: 2869–2881.
11.
SarterMParikhVHoweWM. Phasic acetylcholine release and the volume transmission hypothesis: time to move on. Nat Rev Neurosci2009; 10: 383–390.
12.
MesulamMMMufsonEJLeveyAI, et al.Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol1983; 214: 170–197.
13.
NewmanELGuptaKClimerJR, et al.Cholinergic modulation of cognitive processing: insights drawn from computational models. Front Behav Neurosci2012; 6: 24.
14.
ShinotohHNambaHFukushiK, et al.Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer’s disease: a positron emission tomography study. Ann Neurol2000; 48: 194–200.
15.
ChoHSeoSWKimJ-H, et al.Amyloid deposition in early onset versus late onset Alzheimer’s disease. J Alzheimers Dis2013; 35: 813–821.
16.
YounYCJangJ-WHanS-H, et al.11C-PIB PET imaging reveals that amyloid deposition in cases with early-onset Alzheimer’s disease in the absence of known mutations retains higher levels of PIB in the basal ganglia. Clin Interv Aging2017; 12: 1041–1048.
17.
GiacobiniEGoldG. Alzheimer disease therapy–moving from amyloid-β to tau. Nat Rev Neurol2013; 9: 677–686.
18.
ChoHMundadaNSApostolovaLG, et al.Amyloid and tau-PET in early-onset AD: baseline data from the Longitudinal Early-onset Alzheimer’s Disease Study (LEADS). Alzheimers Dement2023; 19: S98–S114.
19.
ZengQQiuTLiK, et al.Increased functional connectivity between nucleus basalis of Meynert and amygdala in cognitively intact elderly along the Alzheimer’s continuum. Neuroimage Clin2022; 36: 103256.
20.
TagaiKOnoMKubotaM, et al.High-contrast in vivo imaging of tau pathologies in Alzheimer’s and non-Alzheimer’s disease tauopathies. Neuron2021; 109: 42–58.e8.
21.
LuJBaoWLiM, et al.Associations of [18F]-APN-1607 tau PET binding in the brain of Alzheimer’s disease patients with cognition and glucose metabolism. Front Neurosci2020; 14: 604.
22.
EndoHTagaiKOnoM, et al.A machine learning-based approach to discrimination of tauopathies using [18 F]PM-PBB3 PET images. Mov Disord2022; 37: 2236–2246.
23.
BraakHAlafuzoffIArzbergerT, et al.Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol2006; 112: 389–404.
24.
AlafuzoffIPikkarainenMAl-SarrajS, et al.Interlaboratory comparison of assessments of Alzheimer disease-related lesions: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol2006; 65: 740–757.
25.
SaidoTCIwatsuboTMannDMA, et al.Dominant and differential deposition of distinct β-amyloid peptide species, AβN3(pE), in senile plaques. Neuron1995; 14: 457–466.
26.
PetersenRCSmithGEWaringSC, et al.Mild cognitive impairment: clinical characterization and outcome. Arch Neurol1999; 56: 303–308.
27.
McKhannGDrachmanDFolsteinM, et al.Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology1984; 34: 939–944.
28.
FolsteinMFFolsteinSEMcHughPR. Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12: 189–198.
29.
MorrisJC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology1993; 43: 2412–2414.
30.
WilliamsMMRoeCMMorrisJC. Stability of the clinical dementia rating, 1979–2007. Arch Neurol2009; 66: 773–777.
31.
DuboisBSlachevskyALitvanI, et al.The FAB: a frontal assessment battery at bedside. Neurology2000; 55: 1621–1626.
32.
KawamuraKHashimotoHFurutsukaK, et al.Radiosynthesis and quality control testing of the tau imaging positron emission tomography tracer [18 F]PM-PBB3 for clinical applications. J Labelled Comp Radiopharm2021; 64: 109–119.
33.
MaedaJJiBIrieT, et al.Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer’s disease enabled by positron emission tomography. J Neurosci2007; 27: 10957–10968.
34.
KleinATourvilleJ. 101 Labeled brain images and a consistent human cortical labeling protocol. Front Neurosci2012; 6: 171.
35.
ZaborszkyLHoemkeLMohlbergH, et al.Stereotaxic probabilistic maps of the magnocellular cell groups in human basal forebrain. Neuroimage2008; 42: 1127–1141.
36.
AvantsBBEpsteinCLGrossmanM, et al.Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med Image Anal2008; 12: 26–41.
37.
YamaneTIshiiKSakataM, et al.Inter-rater variability of visual interpretation and comparison with quantitative evaluation of 11C-PiB PET amyloid images of the Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI) multicenter study. Eur J Nucl Med Mol Imaging2017; 44: 850–857.
38.
RossorMNFoxNCMummeryCJ, et al.The diagnosis of young-onset dementia. Lancet Neurol2010; 9: 793–806.
39.
UchiharaTNakamuraAYamazakiM, et al.Different conformation of neuronal tau deposits distinguished by double immunofluorescence with AT8 and thiazin red combined with Gallyas method. Acta Neuropathol2001; 102: 462–466.
40.
VogelJWYoungALOxtobyNP, et al.Four distinct trajectories of tau deposition identified in Alzheimer’s disease. Nat Med2021; 27: 871–881.
41.
Fernández-CabelloSKronbichlerMVan DijkKRA, et al.Basal forebrain volume reliably predicts the cortical spread of Alzheimer’s degeneration. Brain2020; 143: 993–1009.
42.
FrisoniGBPievaniMTestaC, et al.The topography of grey matter involvement in early and late onset Alzheimer’s disease. Brain2007; 130: 720–730.
43.
LiuAKLChangRC-CPearceRKB, et al.Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer’s and Parkinson’s disease. Acta Neuropathol2015; 129: 527–540.
44.
TiernanCTMufsonEJKanaanNM, et al.Tau oligomer pathology in nucleus basalis neurons during the progression of Alzheimer disease. J Neuropathol Exp Neurol2018; 77: 246–259.
45.
HoGJHansenLAAlfordMF, et al.Age at onset is associated with disease severity in Lewy body variant and Alzheimer’s disease. Neuroreport2002; 13: 1825–1828.
46.
ChoHChoiJYLeeSH, et al.Excessive tau accumulation in the parieto-occipital cortex characterizes early-onset Alzheimer’s disease. Neurobiol Aging2017; 53: 103–111.
47.
BraakHThalDRGhebremedhinE, et al.Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol2011; 70: 960–969.
48.
LemoineLLeuzyAChiotisK, et al.Tau positron emission tomography imaging in tauopathies: the added hurdle of off-target binding. Alzheimers Dement2018; 10: 232–236.
49.
JangYKLyooCHParkS, et al.Head to head comparison of [18F] AV-1451 and [18F] THK5351 for tau imaging in Alzheimer’s disease and frontotemporal dementia. Eur J Nucl Med Mol Imaging2018; 45: 432–442.
50.
NgKPPascoalTAMathotaarachchiS, et al.Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimers Res Ther2017; 9: 25.
51.
SmirnovDSGalaskoDHinikerA, et al.Age-at-onset and APOE-related heterogeneity in pathologically confirmed sporadic Alzheimer disease. Neurology2021; 96: e2272–e2283.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
